Log in to search using one of your social media accounts:

 

State of the Art Update and Next Questions: Acute Myeloid Leukemia

The past decade has witnessed major advances in our comprehension of the biological heterogeneity of acute myeloid leukemia (AML); however, translating this knowledge into better outcomes for AML patients has lagged. Over the past year, two large, randomized phase III clinical trials with novel therapies produced positive results that are expected to lead to the first new drug approvals in AML in over 40 years.[1, 2] Many other promising drugs are currently under investigation, offering hope that even more novel treatments will be added to the armamentarium in the near future.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research

Related Links:

Conclusion This study did not support associations between night-shift work and hematological cancers.byTalibov M, Pukkala E, Martinsen JI, Tryggvadottir L, Weiderpass E, Hansen J. doi:10.5271/sjweh.3704
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Tags: Original article Source Type: research
Conclusion This study did not support associations between night-shift work and hematological cancers. PMID: 29323398 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Work, Environment and Health - Category: Occupational Health Authors: Tags: Scand J Work Environ Health Source Type: research
CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms, direct apoptotic activity, and immunomodulatory effects b...
Source: Blood - Category: Hematology Authors: Tags: Free Research Articles, Lymphoid Neoplasia, Review Articles, Review Series, Clinical Trials and Observations Source Type: research
There is a need to improve outcomes for patients with recurrent and/or refractory hematological malignancies. Immunotherapy holds the promise to meet this need, because it does not rely on the cytotoxic mechanism of conventional therapies. Among different forms of immunotherapy, redirecting T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy. BsAbs are an "off-the-shelf" product that is easily scalable in contrast to adoptive T-cell therapies. Among these, the bispecific T-cell engager blinatumomab has emerged as the most successful BsAb to date. It consists of 2 sin...
Source: Blood - Category: Hematology Authors: Tags: Immunobiology and Immunotherapy, Review Articles, Review Series Source Type: research
Conclusion Danazol as first-line therapy is an acceptable treatment option with low side effects for patients with MDS who cannot receive ASCT. Micro-Abstract At present, no standard therapy is available for most patients with myelodysplastic syndrome. In this retrospective study, we analyze data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option because of its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 7 December 2017 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Jan Vydra, Cyril Šálek, Jiří Schwarz, Pavel Žák, Jan Novák, Veronika Petečuková, Pavla Pecherková, Jiří Mayer, Petr Cetkovský, Zdeněk Ráčil
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion CLAG plus IM was well tolerated, with encouraging signs of activity in patients with poor-risk AML. Micro-Abstract Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic h...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Patients with AML had a higher sepsis incidence and higher mortality rates overall, especially in relation to stem-cell transplant recipients and those with other types of cancer. Clinical trials are needed to determine whether early intervention or treatment in specialized centers could improve outcomes and reduce costs of care, particularly in the management of serious complications such as sepsis. Micro-Abstract We reviewed outcomes of patients with acute myeloid leukemia (AML) and sepsis in Texas. AML patients (0.25% of > 2 million discharges) had a higher incidence of sepsis (16% vs. 4%) and of sepsis-re...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion Danazol as frontline therapy is an acceptable treatment option with low side effects for patients with MDS that cannot receive ASCT Teaser At present, no standard therapy is available for most patients with myelodysplastic syndromes. In this retrospective study, we analyse data from 42 patients with myelodysplastic syndrome treated with low-dose danazol. More than half achieved a response. Results show that danazol remains an attractive option due to its low cost and good safety profile in centers with reduced access to novel therapeutic alternatives.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease. Micro-Abstract The optimal management of patients with follicular lymphoma grade 3 (FLG3) is controversial. We analyzed 45 patients with FLG3 treated with first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). R-CHOP showed to be an effective first-line treatment for these patients, and provided extended PFS, comparable with outcomes observed in diffuse large...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Clinical Trials | Hematology | Leukemia | Lymphoma | Myeloma